Armata Pharmaceuticals（ARMP）株式概要は、抗生物質耐性感染症に対する標的バクテリオファージ治療薬の開発に注力する臨床段階のバイオテクノロジー企業である。 詳細ARMP ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長2/6過去の実績0/6財務の健全性0/6配当金0/6報酬収益は年間55.45%増加すると予測されています リスク分析マイナスの株主資本 キャッシュランウェイが1年未満である US市場と比較して、過去 3 か月間の株価の変動が非常に大きい現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るARMP Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$8.36120.0% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-423m47m2016201920222025202620282031Revenue US$47.2mEarnings US$8.6mAdvancedSet Fair ValueView all narrativesArmata Pharmaceuticals, Inc. 競合他社Organogenesis HoldingsSymbol: NasdaqCM:ORGOMarket cap: US$342.3mMacroGenicsSymbol: NasdaqGS:MGNXMarket cap: US$269.5mLineage Cell TherapeuticsSymbol: NYSEAM:LCTXMarket cap: US$329.1mMyriad GeneticsSymbol: NasdaqGS:MYGNMarket cap: US$369.3m価格と性能株価の高値、安値、推移の概要Armata Pharmaceuticals過去の株価現在の株価US$8.3652週高値US$16.3452週安値US$1.74ベータ1.321ヶ月の変化-39.90%3ヶ月変化-4.24%1年変化342.33%3年間の変化523.88%5年間の変化109.00%IPOからの変化79.78%最新ニュースReported Earnings • May 15First quarter 2026 earnings released: US$3.16 loss per share (vs US$0.18 loss in 1Q 2025)First quarter 2026 results: US$3.16 loss per share (further deteriorated from US$0.18 loss in 1Q 2025). Net loss: US$115.3m (loss widened US$108.8m from 1Q 2025). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 85% per year, which means it is well ahead of earnings.お知らせ • Apr 28+ 1 more updateArmata Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2026Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2026. Location: 5005 mcconnell avenue, california 90066, los angeles United StatesReported Earnings • Mar 27Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: US$4.80 loss per share (further deteriorated from US$0.52 loss in FY 2024). Net loss: US$173.8m (loss widened US$154.9m from FY 2024). Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) missed analyst estimates by 194%. Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 71% per year, which means it is well ahead of earnings.お知らせ • Feb 24Armata Pharmaceuticals, Inc. Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02Armata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (the "FDA") has granted AP-SA02, the Company's Staphylococcus aureus ("S. aureus") multi-phage product candidate, for intravenous use as a Qualified Infectious Disease Product ("QIDP") for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA"). To achieve QIDP designation, a drug candidate must be intended to treat serious or life-threatening infections, particularly those caused by bacteria and fungi that are resistant to treatment, or that treat qualifying resistant pathogens identified by the FDA. The QIDP designation makes AP-SA02 eligible to benefit from certain incentives for the development of new antibacterials provided under the Generating Antibiotic Incentives Now (GAIN) Act, including an additional five-year extension of Hatch-Waxman market exclusivity. Further, the QIDP designation makes AP-SA02 eligible for Fast Track status, which provides an opportunity for more frequent meetings and communication with the FDA, priority and rolling review, leading to potential accelerated approval of its Biologics License Application. The Company plans to submit to the FDA a request for Fast Track Designation for AP-SA02.お知らせ • Jan 13Armata Pharmaceuticals, Inc. Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated S aureus bacteremiaArmata Pharmaceuticals, Inc. announced the conclusion of an End-of-Phase 2 ("EOP2") written response from the U.S. Food and Drug Administration ("FDA") and plans to advance the Company's intravenously-administered Staphylococcus aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study in complicated S. aureus bacteremia. The Phase 3 study is anticipated to initiate in the second half of 2026. FDA's Center for Biologics Evaluation and Research division, upon reviewing Armata's detailed EOP2 background package, confirmed that the safety and efficacy data from Armata's Phase 2a diSArm study support advancement to Phase 3. The FDA provided critical guidance on key elements of the Phase 3 study design, which will assess the superiority of AP-SA02 over the current standard of care for the treatment of complicated S. aureus Bacteremia. Armata is addressing FDA comments, including on Chemistry, Manufacturing, and Controls ("CMC") and aligning them with the Company's existing Phase 3 manufacturing and quality strategy. The FDA also included recommendations for the future Biologics License Application and is amenable to Armata submitting a request for Qualified Infectious Disease Product Designation ("QIDP") for AP-SA02. The Company is already addressing many of the clinical and CMC comments from FDA and has submitted the request for QIDP. The results of the Phase 2a diSArm trial were announced in May 2025 and further highlighted in a late-breaking oral presentation at IDWeek 2025™? in October 2025. The results of the Phase 2a diSArm study were announced in May 2025 and further highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The primary study endpoint for the Phase 3 superiority study is expected to be clinical response at end of best available antibiotic therapy ("BAT") and 28 days later at End of Study. Safety and healthcare resource impact analyses will be included.お知らせ • Dec 02Armata Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Armata Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering最新情報をもっと見るRecent updatesReported Earnings • May 15First quarter 2026 earnings released: US$3.16 loss per share (vs US$0.18 loss in 1Q 2025)First quarter 2026 results: US$3.16 loss per share (further deteriorated from US$0.18 loss in 1Q 2025). Net loss: US$115.3m (loss widened US$108.8m from 1Q 2025). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 85% per year, which means it is well ahead of earnings.お知らせ • Apr 28+ 1 more updateArmata Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2026Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2026. Location: 5005 mcconnell avenue, california 90066, los angeles United StatesReported Earnings • Mar 27Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: US$4.80 loss per share (further deteriorated from US$0.52 loss in FY 2024). Net loss: US$173.8m (loss widened US$154.9m from FY 2024). Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) missed analyst estimates by 194%. Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 71% per year, which means it is well ahead of earnings.お知らせ • Feb 24Armata Pharmaceuticals, Inc. Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02Armata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (the "FDA") has granted AP-SA02, the Company's Staphylococcus aureus ("S. aureus") multi-phage product candidate, for intravenous use as a Qualified Infectious Disease Product ("QIDP") for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA"). To achieve QIDP designation, a drug candidate must be intended to treat serious or life-threatening infections, particularly those caused by bacteria and fungi that are resistant to treatment, or that treat qualifying resistant pathogens identified by the FDA. The QIDP designation makes AP-SA02 eligible to benefit from certain incentives for the development of new antibacterials provided under the Generating Antibiotic Incentives Now (GAIN) Act, including an additional five-year extension of Hatch-Waxman market exclusivity. Further, the QIDP designation makes AP-SA02 eligible for Fast Track status, which provides an opportunity for more frequent meetings and communication with the FDA, priority and rolling review, leading to potential accelerated approval of its Biologics License Application. The Company plans to submit to the FDA a request for Fast Track Designation for AP-SA02.お知らせ • Jan 13Armata Pharmaceuticals, Inc. Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated S aureus bacteremiaArmata Pharmaceuticals, Inc. announced the conclusion of an End-of-Phase 2 ("EOP2") written response from the U.S. Food and Drug Administration ("FDA") and plans to advance the Company's intravenously-administered Staphylococcus aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study in complicated S. aureus bacteremia. The Phase 3 study is anticipated to initiate in the second half of 2026. FDA's Center for Biologics Evaluation and Research division, upon reviewing Armata's detailed EOP2 background package, confirmed that the safety and efficacy data from Armata's Phase 2a diSArm study support advancement to Phase 3. The FDA provided critical guidance on key elements of the Phase 3 study design, which will assess the superiority of AP-SA02 over the current standard of care for the treatment of complicated S. aureus Bacteremia. Armata is addressing FDA comments, including on Chemistry, Manufacturing, and Controls ("CMC") and aligning them with the Company's existing Phase 3 manufacturing and quality strategy. The FDA also included recommendations for the future Biologics License Application and is amenable to Armata submitting a request for Qualified Infectious Disease Product Designation ("QIDP") for AP-SA02. The Company is already addressing many of the clinical and CMC comments from FDA and has submitted the request for QIDP. The results of the Phase 2a diSArm trial were announced in May 2025 and further highlighted in a late-breaking oral presentation at IDWeek 2025™? in October 2025. The results of the Phase 2a diSArm study were announced in May 2025 and further highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The primary study endpoint for the Phase 3 superiority study is expected to be clinical response at end of best available antibiotic therapy ("BAT") and 28 days later at End of Study. Safety and healthcare resource impact analyses will be included.お知らせ • Dec 02Armata Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Armata Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Oct 22Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus Aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025Armata Pharmaceuticals, Inc. highlighted positive results from its recently completed Phase 2a diSArm study of AP-SA02 as a potential treatment for complicated Staphylococcus aureus ("S. aureus") bacteremia ("SAB") in a late-breaking oral presentation at IDWeek 2025™. The abstract, titled, "A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus auresus Bacteremia," was accepted as a highly coveted late-breaking abstract for oral presentation, and was presented by Dr. Loren G. Miller, M.D., M.P.H., Professor of Medicine, David Geffen School of Medicine at UCLA, Chief, Division of Infectious Diseases at Harbor-UCLA Medical Center and the Lundquist Institute. New findings demonstrate that the defined and reproducible genomic variants present in AP-SA02 Drug Product may provide an immediate advantage, enabling rapid, strain-specific response to each patient's S. aureus isolate. These results strongly support advancement into a pivotal Phase 3 trial that Armata plans to initiate in 2026, subject to review and feedback from the U.S. Food and Drug Administration (the "FDA"). The Company is engaged with the FDA regarding a potential superiority trial design. Armata is developing AP-SA02, a fixed multi-phage phage cocktail, for the treatment of complicated bacteremia caused by Staphylococcus auredus (S. aureus), including methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) strains. The results from the diSArm study are an important step forward in Armata's effort to confirm the potent antimicrobial activity of phage therapy and the completion of the study represents a significant milestone in the development of AP-SA02, moving Armata one step closer to introducing an effective new treatment option to patients suffering from complicated S. aureus bacteremia. The Phase 1b/2a clinical development of AP-SA02 was partially supported by a $26.2 million Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) - Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.お知らせ • Oct 15Armata Pharmaceuticals to Present Late-Breaking Clinical Data Highlighting Its Staphylococcus Aureus Bacteriophage Cocktail, Ap-Sa02, At Idweek 2025Armata Pharmaceuticals, Inc. announced it will be presenting late-breaking Phase 2a clinical data on its Staphylococcus aureus aureus bacteriophage cocktail, AP-SA02, at IDWeek 2025™?, which is being held October 19-22, 2025, in Atlanta, GA. Details of the oral presentation are as follows: Presentation Title: A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus auresus Bacteremia.お知らせ • May 20Armata Pharmaceuticals, Inc. Announces Positive Topline Data from the Phase 1B/2A diSArm Study of Intravenous Administration AP-SA02 in Complicated Staphylococcus Aureus BacteremiaArmata Pharmaceuticals, Inc. announced positive topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous ("IV") administered multi-phage therapeutic for the treatment of Staphylococcus aureus ("S. aureus") bacteremia ("SAB"), in the intent-to-treat ("ITT") population. The primary clinical efficacy endpoint for the Phase 2a portion of the diSArm study was clinical outcome (responder rate) in subjects with complicated bacteremia, measured at (i) Test of Cure ("TOC") for AP-SA02, defined as one week following the end of IV treatment with AP-SA02 (day 12), (ii) TOC for BAT, defined as one week following of IV BAT, and (iii) end of study ("EOS"), defined as four weeks following the end of IV BAT. A statistically significant increase in investigator-assessed responder rate was observed at TOC for AP-SA02 (day12) in AP-SA02 treated subjects (88%) versus placebo (58%) (p = 0.047). At TOC for BAT and at EOS, 100% of the AP-SA02 treated subjects had clinically responded (p = 0.017) versus 25% of placebo subjects considered non-responsive due to either relapse or treatment failure, consistent with the non-responder rate reported in the literature for recent phase 3 trials. Of note, the clinical response with AP-SA02 occurred regardless of whether subjects were infected with methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA"). This clinical trial is groundbreaking in two fundamental ways: firstly, this is the first clear evidence in a randomized controlled trial of the efficacy of phage against a serious systemic pathogen that is responsible for significant morbidity and mortality in the United States, and secondly, Armata was able to successfully produce high titer phage with high purity allowing for repetitive IV administration every six hours without significant safety concerns.Price Target Changed • May 19Price target increased by 24% to US$9.00Up from US$7.25, the current price target is provided by 1 analyst. New target price is 280% above last closing price of US$2.37. Stock is down 4.4% over the past year. The company is forecast to post a net loss per share of US$1.94 next year compared to a net loss per share of US$0.52 last year.New Risk • May 15New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: US$4.7m This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$36m free cash flow). Negative equity (-US$54m). Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (US$4.7m revenue). Market cap is less than US$100m (US$49.9m market cap).Reported Earnings • May 15First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2025 results: US$0.18 loss per share (improved from US$0.69 loss in 1Q 2024). Net loss: US$6.53m (loss narrowed 74% from 1Q 2024). Revenue missed analyst estimates by 64%. Earnings per share (EPS) exceeded analyst estimates by 53%. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.New Risk • Apr 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$39m free cash flow). Negative equity (-US$48m). Earnings have declined by 23% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$71m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$34.7m market cap).お知らせ • Apr 05Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2025Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2025. Location: 5005 mcconnell avenue, california 90066, los angeles United StatesReported Earnings • Mar 21Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: US$0.52 loss per share (improved from US$1.91 loss in FY 2023). Net loss: US$18.9m (loss narrowed 73% from FY 2023). Revenue missed analyst estimates by 5.9%. Earnings per share (EPS) exceeded analyst estimates by 45%. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.お知らせ • Dec 19Armata Pharmaceuticals, Inc. Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa InfectionArmata Pharmaceuticals, Inc. announced encouraging topline results from its Phase 2 ("Tailwind") trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa ("P.a." or "P. aeruginosa") infections in non-cystic fibrosis bronchiectasis ("NCFB") patients. This is the second successful clinical trial AP-PA02, Armata's lead pulmonary candidate, which was first evaluated in cystic fibrosis patients in the Phase 1b/2a SWARM-P.a. trial, completed in 2023. The Tailwind study (NCT05616221) was a multicenter, randomized, double-blind, placebo-controlled trial that evaluated the safety, pharmacokinetics and efficacy of inhaled AP-PA02. The Tailwind study was conducted in two cohorts running in parallel: subjects in one cohort (cohort A) received inhaled AP-PA02 as monotherapy, while subjects in another cohort (cohort B) received inhaled anti-pseudomonal antibiotic treatment. The study data indicate the potential for phage therapy to reduce reliance on chronic antibiotic use. Safety data indicate that inhaled AP-PA02 was well-tolerated with treatment-emergent adverse events mild and self-limiting. The company believe the safety and tolerability of AP-PA02 exhibited a promising profile for treating chronically infected NCFB patients.お知らせ • Dec 06Armata Pharmaceuticals, Inc. Concludes Employment Agreement with Mina Pastagia as Chief Medical OfficerOn November 15, 2024, Armata Pharmaceuticals, Inc. disclosed that it had reached an agreement with Mina Pastagia, M.D. (“Dr. Pastagia”), the Company’s Chief Medical Officer, pursuant to which Dr. Pastagia’s employment had concluded effective as of November 13, 2024. In connection with Dr. Pastagia’s separation, on December 2, 2024, the Company entered into a Separation and Release Agreement with Dr. Pastagia (the “Separation Agreement”) pursuant to which, in consideration for Dr. Pastagia’s general release of claims in favor of the Company and its affiliates, Dr. Pastagia will be entitled to the continued payment of her base salary for twelve months following the Termination Date. Dr. Pastagia’s receipt of the foregoing payments is subject to her non-revocation of and compliance with the Separation Agreement.Reported Earnings • Nov 15Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: US$0.15 loss per share (improved from US$0.86 loss in 3Q 2023). Net loss: US$5.48m (loss narrowed 82% from 3Q 2023). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 46%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.お知らせ • Nov 12Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus BacteremiaArmata Pharmaceuticals, Inc. announced that it has achieved full enrollment (n=50) of its Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for Staphylococcus aureus (S. aureus) bacteremia. Armata anticipates topline data from the diSArm study in the first quarter of 2025. During the Phase 2a portion of diSArm, Armata focused on evaluating clinical safety of higher intravenous doses of AP-SA02 and accelerating enrollment to arrive at topline data expeditiously. The manufacture of highly purified phages using Armata's proprietary methods enabled dose escalation to 5E10 PFU every six hours (2E11 PFU every 24 hours) for five days without clinically significant adverse events. In parallel with dose escalation, the evolution of two distinct blinded subsets of subjects receiving phage has been observed. One subset, comprising approximately half of the treated group, has evidence of persistence of detectable phage in the blood providing early evidence of in vivo phage amplification and resultant release of phage progeny. The Company anticipates topline data from the diSArm study in the first quarter of 2025 where it can explore the two aforementioned subsets in an unblinded manner. Topline results are also expected to inform the optimal dose of AP-SA02 to be evaluated in the larger definitive efficacy study. Armata remains committed to developing a pivotal S. aureus bacteremia trial in 2025 to evaluate the intravenous phage product candidate, AP-SA02, as an adjunct to standard of care broad-spectrum antibiotics and/or potentially as an alternative to broad-spectrum antibiotics. Modern medicine requires a hard look at reliance on broad-spectrum antibiotics and their detrimental impact on the healthy human microbiome. The Company plans to discuss its pivotal trial design with the U.S. Food and Drug Administration. The clinical development of AP-SA02 is supported in part by $21.6 million funds from the Defense Health Agency and Joint Warfighter Medical Research Program received through the MTEC and managed by the NMRC-NAMD. The diSArm study is a Phase 1b/2a, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 as an adjunct to best available antibiotic therapy (BAT) compared to BAT alone for the treatment of adults with bacteremia due to S. aureus. The Phase 1b portion evaluated the safety and tolerability of multiple ascending intravenous doses of AP-SA02 or placebo as an adjunct to BAT compared to BAT alone in subjects with S. aureus bacteremia. The Phase 2a portion evaluated the efficacy, safety, and tolerability of multiple doses of intravenous AP-SA02 or placebo as an adjunct to BAT compared to BAT alone in subjects with complicated S. aureus bacteremia.New Risk • Sep 03New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$46m free cash flow). Negative equity (-US$46m). Earnings are forecast to decline by an average of 2.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$51m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (US$3.7m revenue). Market cap is less than US$100m (US$88.6m market cap).Major Estimate Revision • Aug 20Consensus revenue estimates decrease by 32%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$4.54m to US$3.08m. EPS estimate increased from -US$1.91 to -US$1.04 per share. Biotechs industry in the US expected to see average net income decline 14% next year. Consensus price target of US$8.00 unchanged from last update. Share price fell 13% to US$2.37 over the past week.お知らせ • Aug 16+ 1 more updateArmata Pharmaceuticals Announces Principal Financial Officer ChangesArmata Pharmaceuticals, Inc. announced the appointment of life sciences accounting and finance veteran David House as Principal Financial Officer effective August 16th. Armata's Corporate Controller, Richard Rychlik, will retain the position of Controller. Before joining Armata, Mr. House served as Corporate Controller and Vice President of Accounting at ZO Skin Health, Inc., from October 2018 to May 2024. At ZO Skin Health, he led global accounting operations, managed financial reporting, and played a crucial role in the company's acquisition by Blackstone. He also established international subsidiaries and oversaw financial integration for mergers and acquisitions. Mr. House's experience includes similar financial leadership roles at Peregrine Pharmaceuticals, Inc., and Avid Bioservices, Inc. (CDMO), a contract development and manufacturing organization where he served as Controller and was responsible for implementing ASC 606, managing technical accounting, and conducting Securities and Exchange Commission (the "SEC") reporting. Mr. House's career also includes roles at Viant, Inc. (DSP), Sourcing Solutions, LLC, and Apria Healthcare (APR), where he held various accounting and financial management positions. In the early stages of his career, Mr. House worked as a Senior Auditor at Windes. There, he managed comprehensive audits for public, private, and not-for-profit entities and contributed to SEC filings and internal control evaluations. Mr. House holds a Bachelor of Arts in Business Administration with an Accounting concentration from California State University, Fullerton. He obtained his California Certified Public Accountant license, which is currently inactive.Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: US$0.25 (vs US$0.098 loss in 2Q 2023)Second quarter 2024 results: EPS: US$0.25 (up from US$0.098 loss in 2Q 2023). Net income: US$8.99m (up US$12.5m from 2Q 2023). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.お知らせ • Aug 01Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02Armata Pharmaceuticals, Inc. announced that it has received an additional $5.25 million of non-dilutive funding pursuant to a previously announced Department of Defense grant, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The grant was awarded to Armata to support clinical development of its optimized phage candidate, AP-SA02, as a potential treatment for complicated Staphylococcus aureus bacteremia. The diSArm study is a Phase 1b/2a, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 as an adjunct to best available antibiotic therapy compared to best available antibiotic therapy alone for the treatment of adults with bacteremia due to Staphylococcus aureus. This study is being conducted in two phases: Phase 1b evaluated the safety and tolerability of multiple ascending intravenous doses of AP-SA02 or placebo as an adjunct to best available therapy (BAT) compared to BAT alone in subjects with SA bacteremia (SAB). Phase 2a is evaluating the efficacy, safety, and tolerability of multiple doses of AP-SA02 or placebo as an adjunct to BAT compared to BAT alone in subjects with complicated SAB. The study is expected to enroll approximately 50 subjects. The study is currently 68% enrolled.お知らせ • Jul 11Armata Pharmaceuticals, Inc. Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled Ap-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas Aeruginosa InfectionArmata Pharmaceuticals, Inc. announced that it has achieved full enrollment in its Tailwind Phase 2 clinical study of inhaled AP-PA02 in patients with NCFB and chronic pulmonary Pseudomonas aeruginosa(P. aeruginosa) infection. The last patient final follow-up visit is scheduled for August 7, 2024. Armata anticipates topline data from the Tailwind study in the second half of 2024. The Tailwind study is a Phase 2, multi-center, double blind, randomized, placebo-controlled trial evaluating the safety, tolerability, and efficacy of inhaled AP-PA02 as monotherapy, as well as in combination with inhaled antibiotics in subjects with NCFB and chronic pulmonary P. aeruginosa infection. The primary endpoint is P. aeruginosa recovery in sputum following multiple doses of AP-PA02 administered by inhalation.Major Estimate Revision • May 14Consensus EPS estimates fall by 43%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$4.64m to US$4.54m. Losses expected to increase from US$1.34 per share to US$1.91. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target of US$8.00 unchanged from last update. Share price rose 28% to US$3.21 over the past week.Reported Earnings • May 08First quarter 2024 earnings: EPS and revenues miss analyst expectationsFirst quarter 2024 results: US$0.69 loss per share (further deteriorated from US$0.40 loss in 1Q 2023). Net loss: US$25.0m (loss widened 73% from 1Q 2023). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 123%. Revenue is forecast to grow 9.4% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.Board Change • May 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. CEO & Director Deborah Birx was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 01Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024, at 08:30 Pacific Standard Time. Location: 5005 McConnell Avenue Los Angeles California United States Agenda: To elect seven nominees for director to serve one-year terms expiring at the 2025 Annual Meeting of Shareholders and upon their successors being duly elected and qualified; to approve, on an advisory, non-binding basis, the compensation of named executive officers; to ratify the Audit Committee's selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024; and to conduct any other business properly brought before the meeting or any adjournment or postponement thereof.New Risk • Apr 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$90.4m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$56m free cash flow). Negative equity (-US$32m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$98m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (US$4.5m revenue). Market cap is less than US$100m (US$90.4m market cap).Major Estimate Revision • Mar 28Consensus EPS estimates fall by 52%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.88 to -US$1.34 per share. Revenue forecast of US$4.64m unchanged since last update. Biotechs industry in the US expected to see average net income decline 9.6% next year. Consensus price target of US$8.00 unchanged from last update. Share price rose 16% to US$4.10 over the past week.Reported Earnings • Mar 22Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: US$1.91 loss per share (further deteriorated from US$1.08 loss in FY 2022). Net loss: US$69.0m (loss widened 87% from FY 2022). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) missed analyst estimates by 12%. Revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 9% per year.Reported Earnings • Nov 17Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2023 results: US$0.86 loss per share (further deteriorated from US$0.24 loss in 3Q 2022). Net loss: US$31.2m (loss widened 262% from 3Q 2022). Revenue exceeded analyst estimates by 28%. Earnings per share (EPS) missed analyst estimates by 177%. Revenue is expected to decline by 8.5% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 16%. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • Oct 31Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis ConferenceArmata Pharmaceuticals, Inc. announced that topline data from the Company's Phase 1b/2a SWARM-P.a. clinical trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in people with cystic fibrosis (CF) will be mentioned during the North American Cystic Fibrosis Conference (NACFC) Plenary II session. The conference is being held November 2-4, 2023, at the Phoenix Convention Center in Phoenix, AZ. Armata announced positive topline data from the SWARM-P.a. study in March 2023. Plenary II presentation details: Title: "Micro-Management": The Changing Face of Infections in CF Presenters: Natalie E. West, MD, MHS, Johns Hopkins University Lucas R. Hoffman, MD, PhD, Pediatric Pulmonary, Seattle Children's Hospital Date: Friday, November 3rd Time: 5:00pm – 6:15pm ET Session: Plenary Session II location: North Ballroom A-D.お知らせ • Sep 27Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus AureusArmata Pharmaceuticals, Inc. announced that the first patient has been dosed in the Phase 2a portion of the Company's diSArm study of AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Initiation of the Phase 2a portion of The study follows Data Review Committee (DRC) review of positive safety and tolerability data from the Phase 1b portion. The diSArm study is a Phase 1b/2a, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 as an adjunct to best available antibiotic therapy compared to best available antibiotic therapy alone for the treatment of adults with bacteremia due to Staphylococcus aureus. This study is being conducted in two phases: Phase 1b evaluated the safety and tolerability of multiple ascending intravenous doses of AP-SA02 or placebo as an adjunct to best available therapy (BAT) compared to BAT alone in subjects with SA bacteremia (SAB). The Phase 2a is evaluating the efficacy, safety, and tolerability of multiple doses of AP-SA02 or placebo as an adjunct to BAT compared to BAT alone in subjects with complicated SAB. The study will enroll approximately 50 subjects. Armata has received a $16.3 million award to advance development of AP-SA02 from the Department of Defense through the Medical Technology Enterprise Consortium (MTEC) managed by the Naval Medical Research Command with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.お知らせ • Sep 21+ 1 more updateArmata Pharmaceuticals, Inc. Announces CFO ChangesOn September 15, 2023, Richard Rychlik, Corporate Controller of Armata Pharmaceuticals, Inc., was promoted to serve as Armata’s principal financial officer, replacing Julianne Averill of Danforth Advisors, LLC, who resigned as Chief Financial Officer on the same day. The promotion of Mr. Rychlik is part of Armata’s plan to transition more of its financing and accounting functions to Armata personnel. Armata anticipates that Danforth Advisors, LLC will continue to support Armata during that transition. Mr. Rychlik, age 67, has served as the Company’s Corporate Controller since September 5, 2023. Prior to joining Armata, Mr. Rychlik served as corporate controller at ArmaGen Inc., a clinical stage biopharma research company, acquired by JCR Pharma, from 2017 until September 2023. As corporate controller at ArmaGen Inc., Mr. Rychlik managed financial reporting, prepared budgets and forecasts, and prepared and coordinated due diligence for M&A transactions. His experience also includes similar roles at early-stage life science companies and others in the clean tech sector, as well as consulting roles involving managing financial operations and preparing financial reporting for clients. In 2022, Mr. Rychlik was also a member of a team that supported a successful IPO for Greenlight Biosciences. Prior to that, Mr. Rychlik was a member of a team that supported successful IPOs for Internet Brands Inc. and Ceres Inc., and a venture capital raise for Gevo Inc. Mr. Rychlik has over 15 years’ experience as a controller in traditional manufacturing, where he implemented ERP systems several times as well as efficiency measures improving cash flow and cost savings. He earned a B. Arts at University of Toronto and a B. Commerce at University of Windsor followed by several years in public accounting practice at a regional public accounting firm.Major Estimate Revision • Aug 21Consensus revenue estimates decrease by 44%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$6.67m to US$3.76m. EPS estimate increased from -US$1.32 to -US$1.11 per share. Biotechs industry in the US expected to see average net income decline 6.6% next year. Consensus price target of US$8.00 unchanged from last update. Share price fell 14% to US$3.56 over the past week.New Risk • Aug 16New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: US$4.2m This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$54m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings are forecast to decline by an average of 12% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Revenue is less than US$5m (US$4.2m revenue).Reported Earnings • Aug 15Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: US$0.098 loss per share (improved from US$0.26 loss in 2Q 2022). Net loss: US$3.55m (loss narrowed 62% from 2Q 2022). Revenue missed analyst estimates by 46%. Earnings per share (EPS) exceeded analyst estimates by 73%. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.New Risk • Jul 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$51m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$75m net loss in 3 years). Market cap is less than US$100m (US$56.7m market cap).お知らせ • Jul 12+ 1 more updateArmata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of DirectorsArmata Pharmaceuticals, Inc. announced that Deborah L. Birx will also join Armata's Board of Directors. Deborah L. Birx, M.D. is a world-renowned medical expert who most recently served as the response coordinator of the White House Coronavirus Task Force. Previously, she served as Ambassador-at-Large, when she assumed the role of the Coordinator of the United States Government Activities to Combat HIV/AIDS and U.S. Special Representative for Global Health Diplomacy. Dr. Birx also served as the U.S. Global AIDS Coordinator, overseeing the President's Emergency Plan for AIDS Relief (PEPFAR) at the CDC and as the Director of the U.S. Military HIV Research Program (USMHRP) at the Walter Reed Army Institute of Research. From 1980 until 2008, Dr. Birx served in the United States Army, retiring as a colonel. Dr. Birx has published over 230 manuscripts in peer-reviewed journals, authored nearly a dozen chapters in scientific publications, and developed and patented vaccines. She received her medical degree from the Hershey School of Medicine, Pennsylvania State University, and beginning in 1980, she trained in internal medicine and basic and clinical immunology at the Walter Reed Army Medical Center and the National Institutes of Health. Dr. Birx is board certified in internal medicine, allergy and immunology, and diagnostic and clinical laboratory immunology. Dr. Birx was formerly a member of Innoviva's Board of Directors since March 2021 until July 2023. Dr. Birx resigned from the Board of Innoviva prior to the appointment as Armata's CEO.お知らせ • Jun 28Armata Pharmaceuticals, Inc., Annual General Meeting, Aug 29, 2023Armata Pharmaceuticals, Inc., Annual General Meeting, Aug 29, 2023, at 08:30 Pacific Daylight. Location: 4503 Glencoe Avenue, Marina del Ray, california United StatesReported Earnings • May 13First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.40 loss per share (further deteriorated from US$0.30 loss in 1Q 2022). Net loss: US$14.5m (loss widened 65% from 1Q 2022). Revenue missed analyst estimates by 55%. Earnings per share (EPS) also missed analyst estimates by 25%. Revenue is expected to decline by 19% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 19%. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.お知らせ • May 06+ 1 more updateArmata Pharmaceuticals, Inc. Announces Executive ChangesOn May 1, 2023 (the Termination Date), in connection with the planned closure of the Company’s San Diego, CA office, Armata Pharmaceuticals, Inc. (the Company) terminated the employment of Erin Butler, Vice President, Finance and Administration (and principal accounting officer) of the Company, effective as of close of business on the Termination Date. On May 4, 2023, the Company’s Board of Directors appointed Julianne Averill to serve, effective as of May 2, 2023, as principal accounting officer of the Company. Ms. Averill, age 38, has served as a senior director of Danforth Advisors, LLC since August 2021. Ms. Averill has over 20 years of finance & corporate development leadership experience, providing CFO advisory services and supporting life science organizations with capital raise initiatives, investor relations, and corporate strategy. Prior to Danforth, Ms. Averill held several CFO and other operational executive roles of increasing responsibility at leading public and private companies operating at the intersection of technology and science, including serving as CFO for Alveo Technologies from July 2020 to August 2021; VP Finance & Executive Committee Member for BlackThorn Therapeutics from January 2019 to July 2020; Associate VP, Finance & Accounting, for Manifest MedEx from May 2015 to January 2019, and Director of Financial Reporting for Starwood Waypoint Residential Trust from July 2014 to May 2015. Ms. Averill spent her early career at Deloitte as an audit manager in its life sciences and retail practice. Ms. Averill is licensed as an active Certified Public Accountant in the State of California and is a Society of Human Resource Management Certified Professional. She holds a BS in Business Administration and an MS in Accountancy, both from California State University, Fresno, and has received a certificate in Business and Data Analytics from Harvard University.Reported Earnings • Mar 17Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$1.08 loss per share (further deteriorated from US$0.96 loss in FY 2021). Net loss: US$36.9m (loss widened 59% from FY 2021). Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 1.4%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • Jan 12Armata Pharmaceuticals, Inc. announced that it has received $30 million in funding from Innoviva Strategic Opportunities LLCArmata Pharmaceuticals Inc. entered into a securities purchase agreement with returning investor Innoviva Strategic Opportunities LLC to issue Secured Convertible Loan for gross proceeds of $30,000,000 on January 10, 2023. The company will issue the term loan at an interest rate of 8.0% per annum. The loan has a maturity date of January 10, 2024. Repayment of the Loan is required to be guaranteed by the company’s domestic subsidiaries and foreign material subsidiaries, and the Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.Board Change • Nov 23High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Director Brian Varnum was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Price Target Changed • Nov 16Price target increased to US$8.00Up from US$7.25, the current price target is an average from 2 analysts. New target price is 176% above last closing price of US$2.90. Stock is down 16% over the past year. The company is forecast to post a net loss per share of US$1.07 next year compared to a net loss per share of US$0.96 last year.Reported Earnings • Nov 11Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: US$0.24 loss per share (further deteriorated from US$0.22 loss in 3Q 2021). Net loss: US$8.61m (loss widened 59% from 3Q 2021). Revenue missed analyst estimates by 19%. Earnings per share (EPS) exceeded analyst estimates by 13%. Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Price Target Changed • Aug 25Price target increased to US$8.00Up from US$7.25, the current price target is an average from 2 analysts. New target price is 94% above last closing price of US$4.12. Stock is up 8.4% over the past year. The company is forecast to post a net loss per share of US$1.15 next year compared to a net loss per share of US$0.96 last year.Major Estimate Revision • Aug 18Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$4.49m to US$6.53m. EPS estimate fell from -US$1.01 to -US$1.14 per share. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$7.67 unchanged from last update. Share price fell 4.7% to US$4.05 over the past week.Reported Earnings • Aug 12Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2022 results: US$0.26 loss per share (down from US$0.25 loss in 2Q 2021). Net loss: US$9.22m (loss widened 49% from 2Q 2021). Revenue exceeded analyst estimates by 69%. Earnings per share (EPS) missed analyst estimates by 13%. Over the next year, revenue is expected to shrink by 3.4% compared to a 51% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Major Estimate Revision • May 19Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$4.03m to US$4.49m. EPS estimate fell from -US$0.81 to -US$1.01 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target of US$7.67 unchanged from last update. Share price rose 7.8% to US$4.31 over the past week.Board Change • Apr 27High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. CEO & Director Brian Varnum was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Major Estimate Revision • Mar 24Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$4.93m to US$4.03m. EPS estimate increased from -US$0.89 to -US$0.81 per share. Biotechs industry in the US expected to see average net income decline 46% next year. Consensus price target of US$7.67 unchanged from last update. Share price rose 19% to US$5.11 over the past week.Reported Earnings • Mar 19Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.96 loss per share (up from US$1.35 loss in FY 2020). Net loss: US$23.2m (loss widened 4.4% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.0%. Over the next year, revenue is expected to shrink by 15% compared to a 64% growth forecast for the pharmaceuticals industry in the US.Price Target Changed • Feb 15Price target increased to US$8.00Up from US$7.25, the current price target is an average from 3 analysts. New target price is 55% above last closing price of US$5.16. Stock is down 16% over the past year. The company is forecast to post a net loss per share of US$1.02 next year compared to a net loss per share of US$1.35 last year.Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.22 loss per share (vs US$0.31 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$1.25m (up 334% from 3Q 2020). Net loss: US$5.42m (loss narrowed 6.1% from 3Q 2020).Major Estimate Revision • Aug 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$3.43m to US$4.41m. EPS estimate fell from -US$1.00 to -US$1.04 per share. Biotechs industry in the US expected to see average net income decline 21% next year. Consensus price target of US$7.67 unchanged from last update. Share price fell 3.1% to US$3.75 over the past week.Price Target Changed • May 19Price target increased to US$8.00Up from US$7.25, the current price target is an average from 4 analysts. New target price is 99% above last closing price of US$4.02. Stock is up 28% over the past year.Major Estimate Revision • Mar 25Consensus revenue estimates fall to US$666.7kThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$3.25m to US$666.7k. Forecast losses increased from -US$0.86 to -US$1.08 per share. Biotechs industry in the US expected to see average net income growth of 4.2% next year. Consensus price target up from US$7.25 to US$7.75. Share price was steady at US$5.50 over the past week.Major Estimate Revision • Feb 11Analysts update estimatesThe 2020 consensus revenue estimate was lowered from US$1.01m to US$514.9k. Earning per share (EPS) estimate was unchanged from the last update at -US$1.26. The Biotechs industry in the US is expected to see a 7.2% decline in net income next year. The consensus price target of US$7.25 was unchanged from the last update. Share price is up 8.2% to US$6.33 over the past week.Is New 90 Day High Low • Jan 29New 90-day high: US$5.07The company is up 63% from its price of US$3.12 on 30 October 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period.Is New 90 Day High Low • Dec 12New 90-day low: US$2.83The company is down 16% from its price of US$3.35 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 15Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 34%. Earnings per share (EPS) exceeded analyst estimates by 25%. Over the next year, revenue is forecast to grow 742%, compared to a 383% growth forecast for the Biotechs industry in the US.Is New 90 Day High Low • Nov 13New 90-day high: US$3.94The company is up 14% from its price of US$3.46 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.株主還元ARMPUS BiotechsUS 市場7D3.9%1.2%1.0%1Y342.3%34.9%28.7%株主還元を見る業界別リターン: ARMP過去 1 年間で34.9 % の収益を上げたUS Biotechs業界を上回りました。リターン対市場: ARMP過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。価格変動Is ARMP's price volatile compared to industry and market?ARMP volatilityARMP Average Weekly Movement17.3%Biotechs Industry Average Movement11.0%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: ARMPの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: ARMPの weekly volatility ( 17% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a61Deborah Birxwww.armatapharma.comは、抗生物質耐性感染症に対する標的バクテリオファージ治療薬の開発に注力する臨床段階のバイオテクノロジー企業である。同社は独自のバクテリオファージベースの技術を用いて製品を開発している。同社の製品候補には、黄色ブドウ球菌菌血症治療薬AP-SA02、緑膿菌治療薬AP-PA03などがある。本社はカリフォルニア州ロサンゼルス。の子会社である。もっと見るArmata Pharmaceuticals, Inc. 基礎のまとめArmata Pharmaceuticals の収益と売上を時価総額と比較するとどうか。ARMP 基礎統計学時価総額US$302.00m収益（TTM）-US$282.61m売上高(TTM)US$5.20m59.0xP/Sレシオ-1.1xPER（株価収益率ARMP は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ARMP 損益計算書（TTM）収益US$5.20m売上原価US$15.72m売上総利益-US$10.51mその他の費用US$272.10m収益-US$282.61m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-7.70グロス・マージン-202.13%純利益率-5,432.80%有利子負債／自己資本比率-110.0%ARMP の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 23:53終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Armata Pharmaceuticals, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Joseph PantginisH.C. Wainwright & Co.Debanjana ChatterjeeJonesTrading Institutional Services, LLC
Reported Earnings • May 15First quarter 2026 earnings released: US$3.16 loss per share (vs US$0.18 loss in 1Q 2025)First quarter 2026 results: US$3.16 loss per share (further deteriorated from US$0.18 loss in 1Q 2025). Net loss: US$115.3m (loss widened US$108.8m from 1Q 2025). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 85% per year, which means it is well ahead of earnings.
お知らせ • Apr 28+ 1 more updateArmata Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2026Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2026. Location: 5005 mcconnell avenue, california 90066, los angeles United States
Reported Earnings • Mar 27Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: US$4.80 loss per share (further deteriorated from US$0.52 loss in FY 2024). Net loss: US$173.8m (loss widened US$154.9m from FY 2024). Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) missed analyst estimates by 194%. Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 71% per year, which means it is well ahead of earnings.
お知らせ • Feb 24Armata Pharmaceuticals, Inc. Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02Armata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (the "FDA") has granted AP-SA02, the Company's Staphylococcus aureus ("S. aureus") multi-phage product candidate, for intravenous use as a Qualified Infectious Disease Product ("QIDP") for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA"). To achieve QIDP designation, a drug candidate must be intended to treat serious or life-threatening infections, particularly those caused by bacteria and fungi that are resistant to treatment, or that treat qualifying resistant pathogens identified by the FDA. The QIDP designation makes AP-SA02 eligible to benefit from certain incentives for the development of new antibacterials provided under the Generating Antibiotic Incentives Now (GAIN) Act, including an additional five-year extension of Hatch-Waxman market exclusivity. Further, the QIDP designation makes AP-SA02 eligible for Fast Track status, which provides an opportunity for more frequent meetings and communication with the FDA, priority and rolling review, leading to potential accelerated approval of its Biologics License Application. The Company plans to submit to the FDA a request for Fast Track Designation for AP-SA02.
お知らせ • Jan 13Armata Pharmaceuticals, Inc. Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated S aureus bacteremiaArmata Pharmaceuticals, Inc. announced the conclusion of an End-of-Phase 2 ("EOP2") written response from the U.S. Food and Drug Administration ("FDA") and plans to advance the Company's intravenously-administered Staphylococcus aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study in complicated S. aureus bacteremia. The Phase 3 study is anticipated to initiate in the second half of 2026. FDA's Center for Biologics Evaluation and Research division, upon reviewing Armata's detailed EOP2 background package, confirmed that the safety and efficacy data from Armata's Phase 2a diSArm study support advancement to Phase 3. The FDA provided critical guidance on key elements of the Phase 3 study design, which will assess the superiority of AP-SA02 over the current standard of care for the treatment of complicated S. aureus Bacteremia. Armata is addressing FDA comments, including on Chemistry, Manufacturing, and Controls ("CMC") and aligning them with the Company's existing Phase 3 manufacturing and quality strategy. The FDA also included recommendations for the future Biologics License Application and is amenable to Armata submitting a request for Qualified Infectious Disease Product Designation ("QIDP") for AP-SA02. The Company is already addressing many of the clinical and CMC comments from FDA and has submitted the request for QIDP. The results of the Phase 2a diSArm trial were announced in May 2025 and further highlighted in a late-breaking oral presentation at IDWeek 2025™? in October 2025. The results of the Phase 2a diSArm study were announced in May 2025 and further highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The primary study endpoint for the Phase 3 superiority study is expected to be clinical response at end of best available antibiotic therapy ("BAT") and 28 days later at End of Study. Safety and healthcare resource impact analyses will be included.
お知らせ • Dec 02Armata Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Armata Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
Reported Earnings • May 15First quarter 2026 earnings released: US$3.16 loss per share (vs US$0.18 loss in 1Q 2025)First quarter 2026 results: US$3.16 loss per share (further deteriorated from US$0.18 loss in 1Q 2025). Net loss: US$115.3m (loss widened US$108.8m from 1Q 2025). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 85% per year, which means it is well ahead of earnings.
お知らせ • Apr 28+ 1 more updateArmata Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2026Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2026. Location: 5005 mcconnell avenue, california 90066, los angeles United States
Reported Earnings • Mar 27Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: US$4.80 loss per share (further deteriorated from US$0.52 loss in FY 2024). Net loss: US$173.8m (loss widened US$154.9m from FY 2024). Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) missed analyst estimates by 194%. Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 71% per year, which means it is well ahead of earnings.
お知らせ • Feb 24Armata Pharmaceuticals, Inc. Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02Armata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (the "FDA") has granted AP-SA02, the Company's Staphylococcus aureus ("S. aureus") multi-phage product candidate, for intravenous use as a Qualified Infectious Disease Product ("QIDP") for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA"). To achieve QIDP designation, a drug candidate must be intended to treat serious or life-threatening infections, particularly those caused by bacteria and fungi that are resistant to treatment, or that treat qualifying resistant pathogens identified by the FDA. The QIDP designation makes AP-SA02 eligible to benefit from certain incentives for the development of new antibacterials provided under the Generating Antibiotic Incentives Now (GAIN) Act, including an additional five-year extension of Hatch-Waxman market exclusivity. Further, the QIDP designation makes AP-SA02 eligible for Fast Track status, which provides an opportunity for more frequent meetings and communication with the FDA, priority and rolling review, leading to potential accelerated approval of its Biologics License Application. The Company plans to submit to the FDA a request for Fast Track Designation for AP-SA02.
お知らせ • Jan 13Armata Pharmaceuticals, Inc. Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated S aureus bacteremiaArmata Pharmaceuticals, Inc. announced the conclusion of an End-of-Phase 2 ("EOP2") written response from the U.S. Food and Drug Administration ("FDA") and plans to advance the Company's intravenously-administered Staphylococcus aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study in complicated S. aureus bacteremia. The Phase 3 study is anticipated to initiate in the second half of 2026. FDA's Center for Biologics Evaluation and Research division, upon reviewing Armata's detailed EOP2 background package, confirmed that the safety and efficacy data from Armata's Phase 2a diSArm study support advancement to Phase 3. The FDA provided critical guidance on key elements of the Phase 3 study design, which will assess the superiority of AP-SA02 over the current standard of care for the treatment of complicated S. aureus Bacteremia. Armata is addressing FDA comments, including on Chemistry, Manufacturing, and Controls ("CMC") and aligning them with the Company's existing Phase 3 manufacturing and quality strategy. The FDA also included recommendations for the future Biologics License Application and is amenable to Armata submitting a request for Qualified Infectious Disease Product Designation ("QIDP") for AP-SA02. The Company is already addressing many of the clinical and CMC comments from FDA and has submitted the request for QIDP. The results of the Phase 2a diSArm trial were announced in May 2025 and further highlighted in a late-breaking oral presentation at IDWeek 2025™? in October 2025. The results of the Phase 2a diSArm study were announced in May 2025 and further highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The primary study endpoint for the Phase 3 superiority study is expected to be clinical response at end of best available antibiotic therapy ("BAT") and 28 days later at End of Study. Safety and healthcare resource impact analyses will be included.
お知らせ • Dec 02Armata Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Armata Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Oct 22Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus Aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025Armata Pharmaceuticals, Inc. highlighted positive results from its recently completed Phase 2a diSArm study of AP-SA02 as a potential treatment for complicated Staphylococcus aureus ("S. aureus") bacteremia ("SAB") in a late-breaking oral presentation at IDWeek 2025™. The abstract, titled, "A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus auresus Bacteremia," was accepted as a highly coveted late-breaking abstract for oral presentation, and was presented by Dr. Loren G. Miller, M.D., M.P.H., Professor of Medicine, David Geffen School of Medicine at UCLA, Chief, Division of Infectious Diseases at Harbor-UCLA Medical Center and the Lundquist Institute. New findings demonstrate that the defined and reproducible genomic variants present in AP-SA02 Drug Product may provide an immediate advantage, enabling rapid, strain-specific response to each patient's S. aureus isolate. These results strongly support advancement into a pivotal Phase 3 trial that Armata plans to initiate in 2026, subject to review and feedback from the U.S. Food and Drug Administration (the "FDA"). The Company is engaged with the FDA regarding a potential superiority trial design. Armata is developing AP-SA02, a fixed multi-phage phage cocktail, for the treatment of complicated bacteremia caused by Staphylococcus auredus (S. aureus), including methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) strains. The results from the diSArm study are an important step forward in Armata's effort to confirm the potent antimicrobial activity of phage therapy and the completion of the study represents a significant milestone in the development of AP-SA02, moving Armata one step closer to introducing an effective new treatment option to patients suffering from complicated S. aureus bacteremia. The Phase 1b/2a clinical development of AP-SA02 was partially supported by a $26.2 million Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) - Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.
お知らせ • Oct 15Armata Pharmaceuticals to Present Late-Breaking Clinical Data Highlighting Its Staphylococcus Aureus Bacteriophage Cocktail, Ap-Sa02, At Idweek 2025Armata Pharmaceuticals, Inc. announced it will be presenting late-breaking Phase 2a clinical data on its Staphylococcus aureus aureus bacteriophage cocktail, AP-SA02, at IDWeek 2025™?, which is being held October 19-22, 2025, in Atlanta, GA. Details of the oral presentation are as follows: Presentation Title: A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus auresus Bacteremia.
お知らせ • May 20Armata Pharmaceuticals, Inc. Announces Positive Topline Data from the Phase 1B/2A diSArm Study of Intravenous Administration AP-SA02 in Complicated Staphylococcus Aureus BacteremiaArmata Pharmaceuticals, Inc. announced positive topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous ("IV") administered multi-phage therapeutic for the treatment of Staphylococcus aureus ("S. aureus") bacteremia ("SAB"), in the intent-to-treat ("ITT") population. The primary clinical efficacy endpoint for the Phase 2a portion of the diSArm study was clinical outcome (responder rate) in subjects with complicated bacteremia, measured at (i) Test of Cure ("TOC") for AP-SA02, defined as one week following the end of IV treatment with AP-SA02 (day 12), (ii) TOC for BAT, defined as one week following of IV BAT, and (iii) end of study ("EOS"), defined as four weeks following the end of IV BAT. A statistically significant increase in investigator-assessed responder rate was observed at TOC for AP-SA02 (day12) in AP-SA02 treated subjects (88%) versus placebo (58%) (p = 0.047). At TOC for BAT and at EOS, 100% of the AP-SA02 treated subjects had clinically responded (p = 0.017) versus 25% of placebo subjects considered non-responsive due to either relapse or treatment failure, consistent with the non-responder rate reported in the literature for recent phase 3 trials. Of note, the clinical response with AP-SA02 occurred regardless of whether subjects were infected with methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA"). This clinical trial is groundbreaking in two fundamental ways: firstly, this is the first clear evidence in a randomized controlled trial of the efficacy of phage against a serious systemic pathogen that is responsible for significant morbidity and mortality in the United States, and secondly, Armata was able to successfully produce high titer phage with high purity allowing for repetitive IV administration every six hours without significant safety concerns.
Price Target Changed • May 19Price target increased by 24% to US$9.00Up from US$7.25, the current price target is provided by 1 analyst. New target price is 280% above last closing price of US$2.37. Stock is down 4.4% over the past year. The company is forecast to post a net loss per share of US$1.94 next year compared to a net loss per share of US$0.52 last year.
New Risk • May 15New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: US$4.7m This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$36m free cash flow). Negative equity (-US$54m). Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (US$4.7m revenue). Market cap is less than US$100m (US$49.9m market cap).
Reported Earnings • May 15First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2025 results: US$0.18 loss per share (improved from US$0.69 loss in 1Q 2024). Net loss: US$6.53m (loss narrowed 74% from 1Q 2024). Revenue missed analyst estimates by 64%. Earnings per share (EPS) exceeded analyst estimates by 53%. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
New Risk • Apr 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$39m free cash flow). Negative equity (-US$48m). Earnings have declined by 23% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$71m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$34.7m market cap).
お知らせ • Apr 05Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2025Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2025. Location: 5005 mcconnell avenue, california 90066, los angeles United States
Reported Earnings • Mar 21Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: US$0.52 loss per share (improved from US$1.91 loss in FY 2023). Net loss: US$18.9m (loss narrowed 73% from FY 2023). Revenue missed analyst estimates by 5.9%. Earnings per share (EPS) exceeded analyst estimates by 45%. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.
お知らせ • Dec 19Armata Pharmaceuticals, Inc. Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa InfectionArmata Pharmaceuticals, Inc. announced encouraging topline results from its Phase 2 ("Tailwind") trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa ("P.a." or "P. aeruginosa") infections in non-cystic fibrosis bronchiectasis ("NCFB") patients. This is the second successful clinical trial AP-PA02, Armata's lead pulmonary candidate, which was first evaluated in cystic fibrosis patients in the Phase 1b/2a SWARM-P.a. trial, completed in 2023. The Tailwind study (NCT05616221) was a multicenter, randomized, double-blind, placebo-controlled trial that evaluated the safety, pharmacokinetics and efficacy of inhaled AP-PA02. The Tailwind study was conducted in two cohorts running in parallel: subjects in one cohort (cohort A) received inhaled AP-PA02 as monotherapy, while subjects in another cohort (cohort B) received inhaled anti-pseudomonal antibiotic treatment. The study data indicate the potential for phage therapy to reduce reliance on chronic antibiotic use. Safety data indicate that inhaled AP-PA02 was well-tolerated with treatment-emergent adverse events mild and self-limiting. The company believe the safety and tolerability of AP-PA02 exhibited a promising profile for treating chronically infected NCFB patients.
お知らせ • Dec 06Armata Pharmaceuticals, Inc. Concludes Employment Agreement with Mina Pastagia as Chief Medical OfficerOn November 15, 2024, Armata Pharmaceuticals, Inc. disclosed that it had reached an agreement with Mina Pastagia, M.D. (“Dr. Pastagia”), the Company’s Chief Medical Officer, pursuant to which Dr. Pastagia’s employment had concluded effective as of November 13, 2024. In connection with Dr. Pastagia’s separation, on December 2, 2024, the Company entered into a Separation and Release Agreement with Dr. Pastagia (the “Separation Agreement”) pursuant to which, in consideration for Dr. Pastagia’s general release of claims in favor of the Company and its affiliates, Dr. Pastagia will be entitled to the continued payment of her base salary for twelve months following the Termination Date. Dr. Pastagia’s receipt of the foregoing payments is subject to her non-revocation of and compliance with the Separation Agreement.
Reported Earnings • Nov 15Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: US$0.15 loss per share (improved from US$0.86 loss in 3Q 2023). Net loss: US$5.48m (loss narrowed 82% from 3Q 2023). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 46%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
お知らせ • Nov 12Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus BacteremiaArmata Pharmaceuticals, Inc. announced that it has achieved full enrollment (n=50) of its Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for Staphylococcus aureus (S. aureus) bacteremia. Armata anticipates topline data from the diSArm study in the first quarter of 2025. During the Phase 2a portion of diSArm, Armata focused on evaluating clinical safety of higher intravenous doses of AP-SA02 and accelerating enrollment to arrive at topline data expeditiously. The manufacture of highly purified phages using Armata's proprietary methods enabled dose escalation to 5E10 PFU every six hours (2E11 PFU every 24 hours) for five days without clinically significant adverse events. In parallel with dose escalation, the evolution of two distinct blinded subsets of subjects receiving phage has been observed. One subset, comprising approximately half of the treated group, has evidence of persistence of detectable phage in the blood providing early evidence of in vivo phage amplification and resultant release of phage progeny. The Company anticipates topline data from the diSArm study in the first quarter of 2025 where it can explore the two aforementioned subsets in an unblinded manner. Topline results are also expected to inform the optimal dose of AP-SA02 to be evaluated in the larger definitive efficacy study. Armata remains committed to developing a pivotal S. aureus bacteremia trial in 2025 to evaluate the intravenous phage product candidate, AP-SA02, as an adjunct to standard of care broad-spectrum antibiotics and/or potentially as an alternative to broad-spectrum antibiotics. Modern medicine requires a hard look at reliance on broad-spectrum antibiotics and their detrimental impact on the healthy human microbiome. The Company plans to discuss its pivotal trial design with the U.S. Food and Drug Administration. The clinical development of AP-SA02 is supported in part by $21.6 million funds from the Defense Health Agency and Joint Warfighter Medical Research Program received through the MTEC and managed by the NMRC-NAMD. The diSArm study is a Phase 1b/2a, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 as an adjunct to best available antibiotic therapy (BAT) compared to BAT alone for the treatment of adults with bacteremia due to S. aureus. The Phase 1b portion evaluated the safety and tolerability of multiple ascending intravenous doses of AP-SA02 or placebo as an adjunct to BAT compared to BAT alone in subjects with S. aureus bacteremia. The Phase 2a portion evaluated the efficacy, safety, and tolerability of multiple doses of intravenous AP-SA02 or placebo as an adjunct to BAT compared to BAT alone in subjects with complicated S. aureus bacteremia.
New Risk • Sep 03New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$46m free cash flow). Negative equity (-US$46m). Earnings are forecast to decline by an average of 2.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$51m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (US$3.7m revenue). Market cap is less than US$100m (US$88.6m market cap).
Major Estimate Revision • Aug 20Consensus revenue estimates decrease by 32%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$4.54m to US$3.08m. EPS estimate increased from -US$1.91 to -US$1.04 per share. Biotechs industry in the US expected to see average net income decline 14% next year. Consensus price target of US$8.00 unchanged from last update. Share price fell 13% to US$2.37 over the past week.
お知らせ • Aug 16+ 1 more updateArmata Pharmaceuticals Announces Principal Financial Officer ChangesArmata Pharmaceuticals, Inc. announced the appointment of life sciences accounting and finance veteran David House as Principal Financial Officer effective August 16th. Armata's Corporate Controller, Richard Rychlik, will retain the position of Controller. Before joining Armata, Mr. House served as Corporate Controller and Vice President of Accounting at ZO Skin Health, Inc., from October 2018 to May 2024. At ZO Skin Health, he led global accounting operations, managed financial reporting, and played a crucial role in the company's acquisition by Blackstone. He also established international subsidiaries and oversaw financial integration for mergers and acquisitions. Mr. House's experience includes similar financial leadership roles at Peregrine Pharmaceuticals, Inc., and Avid Bioservices, Inc. (CDMO), a contract development and manufacturing organization where he served as Controller and was responsible for implementing ASC 606, managing technical accounting, and conducting Securities and Exchange Commission (the "SEC") reporting. Mr. House's career also includes roles at Viant, Inc. (DSP), Sourcing Solutions, LLC, and Apria Healthcare (APR), where he held various accounting and financial management positions. In the early stages of his career, Mr. House worked as a Senior Auditor at Windes. There, he managed comprehensive audits for public, private, and not-for-profit entities and contributed to SEC filings and internal control evaluations. Mr. House holds a Bachelor of Arts in Business Administration with an Accounting concentration from California State University, Fullerton. He obtained his California Certified Public Accountant license, which is currently inactive.
Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: US$0.25 (vs US$0.098 loss in 2Q 2023)Second quarter 2024 results: EPS: US$0.25 (up from US$0.098 loss in 2Q 2023). Net income: US$8.99m (up US$12.5m from 2Q 2023). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 01Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02Armata Pharmaceuticals, Inc. announced that it has received an additional $5.25 million of non-dilutive funding pursuant to a previously announced Department of Defense grant, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The grant was awarded to Armata to support clinical development of its optimized phage candidate, AP-SA02, as a potential treatment for complicated Staphylococcus aureus bacteremia. The diSArm study is a Phase 1b/2a, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 as an adjunct to best available antibiotic therapy compared to best available antibiotic therapy alone for the treatment of adults with bacteremia due to Staphylococcus aureus. This study is being conducted in two phases: Phase 1b evaluated the safety and tolerability of multiple ascending intravenous doses of AP-SA02 or placebo as an adjunct to best available therapy (BAT) compared to BAT alone in subjects with SA bacteremia (SAB). Phase 2a is evaluating the efficacy, safety, and tolerability of multiple doses of AP-SA02 or placebo as an adjunct to BAT compared to BAT alone in subjects with complicated SAB. The study is expected to enroll approximately 50 subjects. The study is currently 68% enrolled.
お知らせ • Jul 11Armata Pharmaceuticals, Inc. Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled Ap-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas Aeruginosa InfectionArmata Pharmaceuticals, Inc. announced that it has achieved full enrollment in its Tailwind Phase 2 clinical study of inhaled AP-PA02 in patients with NCFB and chronic pulmonary Pseudomonas aeruginosa(P. aeruginosa) infection. The last patient final follow-up visit is scheduled for August 7, 2024. Armata anticipates topline data from the Tailwind study in the second half of 2024. The Tailwind study is a Phase 2, multi-center, double blind, randomized, placebo-controlled trial evaluating the safety, tolerability, and efficacy of inhaled AP-PA02 as monotherapy, as well as in combination with inhaled antibiotics in subjects with NCFB and chronic pulmonary P. aeruginosa infection. The primary endpoint is P. aeruginosa recovery in sputum following multiple doses of AP-PA02 administered by inhalation.
Major Estimate Revision • May 14Consensus EPS estimates fall by 43%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$4.64m to US$4.54m. Losses expected to increase from US$1.34 per share to US$1.91. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target of US$8.00 unchanged from last update. Share price rose 28% to US$3.21 over the past week.
Reported Earnings • May 08First quarter 2024 earnings: EPS and revenues miss analyst expectationsFirst quarter 2024 results: US$0.69 loss per share (further deteriorated from US$0.40 loss in 1Q 2023). Net loss: US$25.0m (loss widened 73% from 1Q 2023). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 123%. Revenue is forecast to grow 9.4% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
Board Change • May 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. CEO & Director Deborah Birx was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 01Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024, at 08:30 Pacific Standard Time. Location: 5005 McConnell Avenue Los Angeles California United States Agenda: To elect seven nominees for director to serve one-year terms expiring at the 2025 Annual Meeting of Shareholders and upon their successors being duly elected and qualified; to approve, on an advisory, non-binding basis, the compensation of named executive officers; to ratify the Audit Committee's selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024; and to conduct any other business properly brought before the meeting or any adjournment or postponement thereof.
New Risk • Apr 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$90.4m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$56m free cash flow). Negative equity (-US$32m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$98m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (US$4.5m revenue). Market cap is less than US$100m (US$90.4m market cap).
Major Estimate Revision • Mar 28Consensus EPS estimates fall by 52%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.88 to -US$1.34 per share. Revenue forecast of US$4.64m unchanged since last update. Biotechs industry in the US expected to see average net income decline 9.6% next year. Consensus price target of US$8.00 unchanged from last update. Share price rose 16% to US$4.10 over the past week.
Reported Earnings • Mar 22Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: US$1.91 loss per share (further deteriorated from US$1.08 loss in FY 2022). Net loss: US$69.0m (loss widened 87% from FY 2022). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) missed analyst estimates by 12%. Revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 9% per year.
Reported Earnings • Nov 17Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2023 results: US$0.86 loss per share (further deteriorated from US$0.24 loss in 3Q 2022). Net loss: US$31.2m (loss widened 262% from 3Q 2022). Revenue exceeded analyst estimates by 28%. Earnings per share (EPS) missed analyst estimates by 177%. Revenue is expected to decline by 8.5% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 16%. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • Oct 31Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis ConferenceArmata Pharmaceuticals, Inc. announced that topline data from the Company's Phase 1b/2a SWARM-P.a. clinical trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in people with cystic fibrosis (CF) will be mentioned during the North American Cystic Fibrosis Conference (NACFC) Plenary II session. The conference is being held November 2-4, 2023, at the Phoenix Convention Center in Phoenix, AZ. Armata announced positive topline data from the SWARM-P.a. study in March 2023. Plenary II presentation details: Title: "Micro-Management": The Changing Face of Infections in CF Presenters: Natalie E. West, MD, MHS, Johns Hopkins University Lucas R. Hoffman, MD, PhD, Pediatric Pulmonary, Seattle Children's Hospital Date: Friday, November 3rd Time: 5:00pm – 6:15pm ET Session: Plenary Session II location: North Ballroom A-D.
お知らせ • Sep 27Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus AureusArmata Pharmaceuticals, Inc. announced that the first patient has been dosed in the Phase 2a portion of the Company's diSArm study of AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Initiation of the Phase 2a portion of The study follows Data Review Committee (DRC) review of positive safety and tolerability data from the Phase 1b portion. The diSArm study is a Phase 1b/2a, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 as an adjunct to best available antibiotic therapy compared to best available antibiotic therapy alone for the treatment of adults with bacteremia due to Staphylococcus aureus. This study is being conducted in two phases: Phase 1b evaluated the safety and tolerability of multiple ascending intravenous doses of AP-SA02 or placebo as an adjunct to best available therapy (BAT) compared to BAT alone in subjects with SA bacteremia (SAB). The Phase 2a is evaluating the efficacy, safety, and tolerability of multiple doses of AP-SA02 or placebo as an adjunct to BAT compared to BAT alone in subjects with complicated SAB. The study will enroll approximately 50 subjects. Armata has received a $16.3 million award to advance development of AP-SA02 from the Department of Defense through the Medical Technology Enterprise Consortium (MTEC) managed by the Naval Medical Research Command with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.
お知らせ • Sep 21+ 1 more updateArmata Pharmaceuticals, Inc. Announces CFO ChangesOn September 15, 2023, Richard Rychlik, Corporate Controller of Armata Pharmaceuticals, Inc., was promoted to serve as Armata’s principal financial officer, replacing Julianne Averill of Danforth Advisors, LLC, who resigned as Chief Financial Officer on the same day. The promotion of Mr. Rychlik is part of Armata’s plan to transition more of its financing and accounting functions to Armata personnel. Armata anticipates that Danforth Advisors, LLC will continue to support Armata during that transition. Mr. Rychlik, age 67, has served as the Company’s Corporate Controller since September 5, 2023. Prior to joining Armata, Mr. Rychlik served as corporate controller at ArmaGen Inc., a clinical stage biopharma research company, acquired by JCR Pharma, from 2017 until September 2023. As corporate controller at ArmaGen Inc., Mr. Rychlik managed financial reporting, prepared budgets and forecasts, and prepared and coordinated due diligence for M&A transactions. His experience also includes similar roles at early-stage life science companies and others in the clean tech sector, as well as consulting roles involving managing financial operations and preparing financial reporting for clients. In 2022, Mr. Rychlik was also a member of a team that supported a successful IPO for Greenlight Biosciences. Prior to that, Mr. Rychlik was a member of a team that supported successful IPOs for Internet Brands Inc. and Ceres Inc., and a venture capital raise for Gevo Inc. Mr. Rychlik has over 15 years’ experience as a controller in traditional manufacturing, where he implemented ERP systems several times as well as efficiency measures improving cash flow and cost savings. He earned a B. Arts at University of Toronto and a B. Commerce at University of Windsor followed by several years in public accounting practice at a regional public accounting firm.
Major Estimate Revision • Aug 21Consensus revenue estimates decrease by 44%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$6.67m to US$3.76m. EPS estimate increased from -US$1.32 to -US$1.11 per share. Biotechs industry in the US expected to see average net income decline 6.6% next year. Consensus price target of US$8.00 unchanged from last update. Share price fell 14% to US$3.56 over the past week.
New Risk • Aug 16New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: US$4.2m This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$54m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings are forecast to decline by an average of 12% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Revenue is less than US$5m (US$4.2m revenue).
Reported Earnings • Aug 15Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: US$0.098 loss per share (improved from US$0.26 loss in 2Q 2022). Net loss: US$3.55m (loss narrowed 62% from 2Q 2022). Revenue missed analyst estimates by 46%. Earnings per share (EPS) exceeded analyst estimates by 73%. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
New Risk • Jul 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$51m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$75m net loss in 3 years). Market cap is less than US$100m (US$56.7m market cap).
お知らせ • Jul 12+ 1 more updateArmata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of DirectorsArmata Pharmaceuticals, Inc. announced that Deborah L. Birx will also join Armata's Board of Directors. Deborah L. Birx, M.D. is a world-renowned medical expert who most recently served as the response coordinator of the White House Coronavirus Task Force. Previously, she served as Ambassador-at-Large, when she assumed the role of the Coordinator of the United States Government Activities to Combat HIV/AIDS and U.S. Special Representative for Global Health Diplomacy. Dr. Birx also served as the U.S. Global AIDS Coordinator, overseeing the President's Emergency Plan for AIDS Relief (PEPFAR) at the CDC and as the Director of the U.S. Military HIV Research Program (USMHRP) at the Walter Reed Army Institute of Research. From 1980 until 2008, Dr. Birx served in the United States Army, retiring as a colonel. Dr. Birx has published over 230 manuscripts in peer-reviewed journals, authored nearly a dozen chapters in scientific publications, and developed and patented vaccines. She received her medical degree from the Hershey School of Medicine, Pennsylvania State University, and beginning in 1980, she trained in internal medicine and basic and clinical immunology at the Walter Reed Army Medical Center and the National Institutes of Health. Dr. Birx is board certified in internal medicine, allergy and immunology, and diagnostic and clinical laboratory immunology. Dr. Birx was formerly a member of Innoviva's Board of Directors since March 2021 until July 2023. Dr. Birx resigned from the Board of Innoviva prior to the appointment as Armata's CEO.
お知らせ • Jun 28Armata Pharmaceuticals, Inc., Annual General Meeting, Aug 29, 2023Armata Pharmaceuticals, Inc., Annual General Meeting, Aug 29, 2023, at 08:30 Pacific Daylight. Location: 4503 Glencoe Avenue, Marina del Ray, california United States
Reported Earnings • May 13First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.40 loss per share (further deteriorated from US$0.30 loss in 1Q 2022). Net loss: US$14.5m (loss widened 65% from 1Q 2022). Revenue missed analyst estimates by 55%. Earnings per share (EPS) also missed analyst estimates by 25%. Revenue is expected to decline by 19% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 19%. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
お知らせ • May 06+ 1 more updateArmata Pharmaceuticals, Inc. Announces Executive ChangesOn May 1, 2023 (the Termination Date), in connection with the planned closure of the Company’s San Diego, CA office, Armata Pharmaceuticals, Inc. (the Company) terminated the employment of Erin Butler, Vice President, Finance and Administration (and principal accounting officer) of the Company, effective as of close of business on the Termination Date. On May 4, 2023, the Company’s Board of Directors appointed Julianne Averill to serve, effective as of May 2, 2023, as principal accounting officer of the Company. Ms. Averill, age 38, has served as a senior director of Danforth Advisors, LLC since August 2021. Ms. Averill has over 20 years of finance & corporate development leadership experience, providing CFO advisory services and supporting life science organizations with capital raise initiatives, investor relations, and corporate strategy. Prior to Danforth, Ms. Averill held several CFO and other operational executive roles of increasing responsibility at leading public and private companies operating at the intersection of technology and science, including serving as CFO for Alveo Technologies from July 2020 to August 2021; VP Finance & Executive Committee Member for BlackThorn Therapeutics from January 2019 to July 2020; Associate VP, Finance & Accounting, for Manifest MedEx from May 2015 to January 2019, and Director of Financial Reporting for Starwood Waypoint Residential Trust from July 2014 to May 2015. Ms. Averill spent her early career at Deloitte as an audit manager in its life sciences and retail practice. Ms. Averill is licensed as an active Certified Public Accountant in the State of California and is a Society of Human Resource Management Certified Professional. She holds a BS in Business Administration and an MS in Accountancy, both from California State University, Fresno, and has received a certificate in Business and Data Analytics from Harvard University.
Reported Earnings • Mar 17Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$1.08 loss per share (further deteriorated from US$0.96 loss in FY 2021). Net loss: US$36.9m (loss widened 59% from FY 2021). Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 1.4%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • Jan 12Armata Pharmaceuticals, Inc. announced that it has received $30 million in funding from Innoviva Strategic Opportunities LLCArmata Pharmaceuticals Inc. entered into a securities purchase agreement with returning investor Innoviva Strategic Opportunities LLC to issue Secured Convertible Loan for gross proceeds of $30,000,000 on January 10, 2023. The company will issue the term loan at an interest rate of 8.0% per annum. The loan has a maturity date of January 10, 2024. Repayment of the Loan is required to be guaranteed by the company’s domestic subsidiaries and foreign material subsidiaries, and the Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.
Board Change • Nov 23High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Director Brian Varnum was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Price Target Changed • Nov 16Price target increased to US$8.00Up from US$7.25, the current price target is an average from 2 analysts. New target price is 176% above last closing price of US$2.90. Stock is down 16% over the past year. The company is forecast to post a net loss per share of US$1.07 next year compared to a net loss per share of US$0.96 last year.
Reported Earnings • Nov 11Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: US$0.24 loss per share (further deteriorated from US$0.22 loss in 3Q 2021). Net loss: US$8.61m (loss widened 59% from 3Q 2021). Revenue missed analyst estimates by 19%. Earnings per share (EPS) exceeded analyst estimates by 13%. Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Price Target Changed • Aug 25Price target increased to US$8.00Up from US$7.25, the current price target is an average from 2 analysts. New target price is 94% above last closing price of US$4.12. Stock is up 8.4% over the past year. The company is forecast to post a net loss per share of US$1.15 next year compared to a net loss per share of US$0.96 last year.
Major Estimate Revision • Aug 18Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$4.49m to US$6.53m. EPS estimate fell from -US$1.01 to -US$1.14 per share. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$7.67 unchanged from last update. Share price fell 4.7% to US$4.05 over the past week.
Reported Earnings • Aug 12Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2022 results: US$0.26 loss per share (down from US$0.25 loss in 2Q 2021). Net loss: US$9.22m (loss widened 49% from 2Q 2021). Revenue exceeded analyst estimates by 69%. Earnings per share (EPS) missed analyst estimates by 13%. Over the next year, revenue is expected to shrink by 3.4% compared to a 51% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Major Estimate Revision • May 19Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$4.03m to US$4.49m. EPS estimate fell from -US$0.81 to -US$1.01 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target of US$7.67 unchanged from last update. Share price rose 7.8% to US$4.31 over the past week.
Board Change • Apr 27High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. CEO & Director Brian Varnum was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Major Estimate Revision • Mar 24Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$4.93m to US$4.03m. EPS estimate increased from -US$0.89 to -US$0.81 per share. Biotechs industry in the US expected to see average net income decline 46% next year. Consensus price target of US$7.67 unchanged from last update. Share price rose 19% to US$5.11 over the past week.
Reported Earnings • Mar 19Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.96 loss per share (up from US$1.35 loss in FY 2020). Net loss: US$23.2m (loss widened 4.4% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.0%. Over the next year, revenue is expected to shrink by 15% compared to a 64% growth forecast for the pharmaceuticals industry in the US.
Price Target Changed • Feb 15Price target increased to US$8.00Up from US$7.25, the current price target is an average from 3 analysts. New target price is 55% above last closing price of US$5.16. Stock is down 16% over the past year. The company is forecast to post a net loss per share of US$1.02 next year compared to a net loss per share of US$1.35 last year.
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.22 loss per share (vs US$0.31 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$1.25m (up 334% from 3Q 2020). Net loss: US$5.42m (loss narrowed 6.1% from 3Q 2020).
Major Estimate Revision • Aug 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$3.43m to US$4.41m. EPS estimate fell from -US$1.00 to -US$1.04 per share. Biotechs industry in the US expected to see average net income decline 21% next year. Consensus price target of US$7.67 unchanged from last update. Share price fell 3.1% to US$3.75 over the past week.
Price Target Changed • May 19Price target increased to US$8.00Up from US$7.25, the current price target is an average from 4 analysts. New target price is 99% above last closing price of US$4.02. Stock is up 28% over the past year.
Major Estimate Revision • Mar 25Consensus revenue estimates fall to US$666.7kThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$3.25m to US$666.7k. Forecast losses increased from -US$0.86 to -US$1.08 per share. Biotechs industry in the US expected to see average net income growth of 4.2% next year. Consensus price target up from US$7.25 to US$7.75. Share price was steady at US$5.50 over the past week.
Major Estimate Revision • Feb 11Analysts update estimatesThe 2020 consensus revenue estimate was lowered from US$1.01m to US$514.9k. Earning per share (EPS) estimate was unchanged from the last update at -US$1.26. The Biotechs industry in the US is expected to see a 7.2% decline in net income next year. The consensus price target of US$7.25 was unchanged from the last update. Share price is up 8.2% to US$6.33 over the past week.
Is New 90 Day High Low • Jan 29New 90-day high: US$5.07The company is up 63% from its price of US$3.12 on 30 October 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period.
Is New 90 Day High Low • Dec 12New 90-day low: US$2.83The company is down 16% from its price of US$3.35 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 15Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 34%. Earnings per share (EPS) exceeded analyst estimates by 25%. Over the next year, revenue is forecast to grow 742%, compared to a 383% growth forecast for the Biotechs industry in the US.
Is New 90 Day High Low • Nov 13New 90-day high: US$3.94The company is up 14% from its price of US$3.46 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
